Correlation Between Anixa Biosciences and Fennec Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Anixa Biosciences and Fennec Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Anixa Biosciences and Fennec Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Anixa Biosciences and Fennec Pharmaceuticals, you can compare the effects of market volatilities on Anixa Biosciences and Fennec Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Anixa Biosciences with a short position of Fennec Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Anixa Biosciences and Fennec Pharmaceuticals.

Diversification Opportunities for Anixa Biosciences and Fennec Pharmaceuticals

0.18
  Correlation Coefficient

Average diversification

The 3 months correlation between Anixa and Fennec is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding Anixa Biosciences and Fennec Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Fennec Pharmaceuticals and Anixa Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Anixa Biosciences are associated (or correlated) with Fennec Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Fennec Pharmaceuticals has no effect on the direction of Anixa Biosciences i.e., Anixa Biosciences and Fennec Pharmaceuticals go up and down completely randomly.

Pair Corralation between Anixa Biosciences and Fennec Pharmaceuticals

Given the investment horizon of 90 days Anixa Biosciences is expected to generate 3.66 times less return on investment than Fennec Pharmaceuticals. But when comparing it to its historical volatility, Anixa Biosciences is 1.03 times less risky than Fennec Pharmaceuticals. It trades about 0.04 of its potential returns per unit of risk. Fennec Pharmaceuticals is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest  458.00  in Fennec Pharmaceuticals on August 25, 2024 and sell it today you would earn a total of  74.00  from holding Fennec Pharmaceuticals or generate 16.16% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Anixa Biosciences  vs.  Fennec Pharmaceuticals

 Performance 
       Timeline  
Anixa Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Anixa Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, Anixa Biosciences is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Fennec Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Fennec Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Fennec Pharmaceuticals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Anixa Biosciences and Fennec Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Anixa Biosciences and Fennec Pharmaceuticals

The main advantage of trading using opposite Anixa Biosciences and Fennec Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Anixa Biosciences position performs unexpectedly, Fennec Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fennec Pharmaceuticals will offset losses from the drop in Fennec Pharmaceuticals' long position.
The idea behind Anixa Biosciences and Fennec Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance